Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
Author:
Open Access
- 5 November 2022
- journal article
- research article
- Published by Elsevier in JACC: Heart Failure
- Vol. 11 (1) , 106-114
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemiaAmerican Journal of Hematology, 2013
- Iron status in patients with chronic heart failureEuropean Heart Journal, 2012
- Soluble TNFα receptor type I and hepcidin as determinants of development of anemia in the long-term follow-up of heart failure patientsClinical Biochemistry, 2012
- The Acetylase/Deacetylase Couple CREB-binding Protein/Sirtuin 1 Controls Hypoxia-inducible Factor 2 SignalingJournal of Biological Chemistry, 2012
- Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosolProceedings of the National Academy of Sciences, 2010
- Etiology of Anemia in Patients With Advanced Heart FailureJACC, 2006
- A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKDKidney International, 2005
- Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failureEuropean Heart Journal, 2005
- Darbepoetin Alfa Effectively Treats Anemia in Patients with Chronic Kidney Disease with de novo Every-Other-Week AdministrationAmerican Journal of Nephrology, 2004
- Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase proteinBlood, 2003